REGISTERED NUMBER: 15189304 (England and Wales)

FINANCIAL STATEMENTS

FOR THE PERIOD 5TH OCTOBER 2023 TO 31ST MARCH 2025

FOR

KC PHARMACEUTICALS LTD

Page

Company Information

1

Abridged Balance Sheet

2

Notes to the Financial Statements

4

DIRECTORS:

K Li

C Li

REGISTERED OFFICE:

8 Upper Folderings

Dodworth

Barnsley

S75 3EE

REGISTERED NUMBER:

15189304 (England and Wales)

ACCOUNTANTS:

Jamie Sutton Accountancy Ltd

Broadfield House

18 Broadfield Road

Sheffield

S8 0XJ

FIXED ASSETS

Investments

4

1,142,445

CURRENT ASSETS

Cash at bank and in hand

11,002

CREDITORS

Amounts falling due within one year

349,488

NET CURRENT LIABILITIES

(338,486

)

TOTAL ASSETS LESS CURRENT LIABILITIES

803,959

CREDITORS

Amounts falling due after more than one year

5

578,523

NET ASSETS

225,436

CAPITAL AND RESERVES

Called up share capital

5

Retained earnings

225,431

225,436

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31st March 2025.

The members have not required the company to obtain an audit of its financial statements for the period ended 31st March 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

All the members have consented to the preparation of an abridged Balance Sheet for the period ended 31st March 2025 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 29th September 2025 and were signed on its behalf by:

K Li - Director

1.	STATUTORY INFORMATION

KC Pharmaceuticals Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Investments in subsidiaries

Investments in subsidiary undertakings are recognised at cost.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the period was 2 .

4.	FIXED ASSET INVESTMENTS

Information on investments other than loans is as follows:

Totals

£

COST

Additions

1,142,445

At 31st March 2025

1,142,445

NET BOOK VALUE

At 31st March 2025

1,142,445

5.

CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN FIVE YEARS

£

Repayable by instalments

Bank loans

398,107

6.	ULTIMATE CONTROLLING PARTY

KC Pharmaceuticals Ltd owns 10% of the share capital of H & K Healthcare Ltd. KC Pharmaceuticals Ltd is 60 % owned by JCK Healthcare Limited and 40% by Ken Li. Ken Li and his wife own 50% of the share capital in JCK Healthcare Limited.